In a mouse endothelial-cell/human-neutrophil adhesion assay, 1–10 μM honokiol pretreatment reduced TNF-α-induced adhesion. Endothelial viability was unchanged in the separate 6 h control. Effects on neutrophils may also contribute to the adhesion result. [1]
TNF-α-induced neutrophil adhesion to cerebral endothelial cells
Cell-based study · Mouse bEnd.3 cerebral endothelial cells with human neutrophils from healthy volunteers [1]
Honokiol decreased neutrophil adhesion following TNF-α stimulation. A separate viability control showed no loss of endothelial viability under the tested 6 h condition. Direct effects on neutrophils may contribute.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1, 3 and 10 μM
- Exposure duration
- 30 min pretreatment; TNF-α for 3 h, then neutrophil adhesion for 30 min; viability control: TNF-α for 6 h
- Method
- Microscopy-based adhesion and WST-1 viability assays
- Vehicle
- 0.1% DMSO
- Co-treatment
- TNF-α 10 ng/ml inflammatory stimulus; compared with DMSO and TNF-α alone
- Reported limits
- Donor count is not specified for this selected experiment; n=5 experiments performed in duplicate is not a donor count.
Methods and source locations
Compound reported in the paper: Honokiol; Compound label in the paper: honokiol
Compound-level research findings only; tested material does not validate Adooq lots or clinical efficacy.
Fig. 1A,C–E; Results: Honokiol suppressed TNF-α-induced neutrophil adhesion; Methods: material identity, cell culture, neutrophil adhesion, viability, statistics
Adherent human neutrophils on bEnd.3 monolayers: DiI-labelled neutrophil adhesion microscopy; mean ± SEM from 5 experiments in duplicate — Fig. 1C,D and caption; corresponding Results
Endothelial viability with TNF-α: WST-1; mean ± SEM from 5 experiments in duplicate — Fig. 1E and caption; Methods: Cell viability assay
IκBα preservation and reduced NF-κB nuclear translocation
Cell-based study · Mouse bEnd.3 cerebral endothelial cells [1]
Honokiol preserved IκBα and reduced TNF-α-induced p65 nuclear localization. MG132 controls did not show significant suppression of IκBα phosphorylation by honokiol. GABA-A antagonist SR95531 did not reverse IκBα preservation.
Literature-Reported Treatment Conditions
- Treatment concentration
- 3 μM
- Exposure duration
- 30 min pretreatment; TNF-α for 15 min in microscopy; 5–30 min in immunoblot time course
- Method
- Immunofluorescence/confocal microscopy and tubulin-normalized immunoblotting
- Vehicle
- 0.1% DMSO
- Co-treatment
- TNF-α 10 ng/ml; mechanistic controls: MG132 5 μM for 1 h, or SR95531 20 μM for 30 min; muscimol 100 μM comparator
- Reported limits
- No biochemical affinity, target selectivity or IC50 established by these experiments.
Methods and source locations
Compound reported in the paper: Honokiol; Compound label in the paper: honokiol
Compound-level research findings only; tested material does not validate Adooq lots or clinical efficacy.
Figs. 3A,B and 4A–E; corresponding Results; Methods: immunofluorescence, immunoblot, material identity, statistics
TNF-α-induced p65 localization and IκBα loss: Microscopy (Fig. 3) and tubulin-normalized immunoblot time course (Fig. 4A,B) — Figs. 3A,B and 4A,B; Results: Honokiol prevented NF-κB nuclear translocation
IκBα phosphorylation and GABA-A dependence controls: Immunoblotting; 3 independent experiments, mean ± SEM — Fig. 4C–E and corresponding Results
Subunit- and agonist-dependent GABA-A receptor potentiation
Cell-based study · HEK-293T cells expressing recombinant α1β3γ2 or α1β3δ GABA-A receptors [2]
Honokiol potentiated responses to low GABA concentrations. δ-containing receptors had lower apparent potency but greater maximal response than γ2-containing receptors. At saturating GABA, honokiol did not increase the γ2 receptor peak response.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.01–30 μM for concentration-response curves; 10 μM for saturating-GABA control
- Exposure duration
- 5 s co-applications
- Method
- Whole-cell voltage clamp at −50 mV
- Vehicle
- DMSO ≤0.01%
- Co-treatment
- GABA 1 μM for α1β3γ2 and 0.3 μM for α1β3δ; saturating control: GABA 1 mM. Magnolol was a separate comparator.
- Reported limits
- Potencies are assay-dependent modulation EC50 values, not binding affinities or inhibitory IC50 values.
Methods and source locations
Compound reported in the paper: Honokiol; Compound label in the paper: honokiol
Compound-level research findings only; tested material does not validate Adooq lots or clinical efficacy.
Methods 2.2 and 2.4; Results 3.2–3.3; Figs. 2–3 and captions
Potentiation of response to 1 μM GABA at α1β3γ2 receptors: Whole-cell concentration-response fit; response relative to GABA alone — Results 3.2; Fig. 2A,B and caption
Potentiation of response to 0.3 μM GABA at α1β3δ receptors: Whole-cell concentration-response fit; response relative to GABA alone — Results 3.2; Fig. 2A,B and caption
Peak response to 1 mM GABA with 10 μM honokiol: Whole-cell recordings; Fig. 3B mean ± SEM; no exact percentage read from bars — Results 3.3; Fig. 3A,B and caption